Another promising nanobody (vobarilizumab/ALX-0061, Ablynx), currently in a phase II trial for treatment of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), is directed against the Interleukin-6 Receptor (IL-6R) (Van Roy et al. 2015). This evidence concerns the gene IL6R and rheumatoid arthritis.